Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## **Revision of Precautions** Secukinumab (genetical recombination)

October 23, 2018

## Non-proprietary name

Secukinumab (genetical recombination)

## Safety measure

Precautions should be revised in the package insert.

The language in the Careful Administration section concerning patients with active Crohn's disease should be revised as follows (revised language is underlined):

Patients with inflammatory bowel disease

The following language should be added to the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section (revised language is underlined):

Inflammatory bowel disease:

Inflammatory bowel disease may occur. Patients should be carefully monitored, and if inflammatory bowel disease is suspected, appropriate measures should be taken.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3·3·2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>